CrossBridge Bio

CrossBridge Bio is a biotechnology firm established in 2023, concentrating on the development of next-generation antibody-drug conjugates (ADCs) for targeted cancer therapy. The company's foundation is built upon the research of its co-founders, Dr. Kyoji Tsuchikama and Dr. Zhiqiang An, from UTHealth Houston. Dr. Tsuchikama is recognized for his work in ADCs, while Dr. An serves as the Director of the Texas Therapeutics Institute. The CEO and co-founder, Dr. Michael Torres, transitioned from an Entrepreneur in Residence role at the Texas Medical Center's Accelerator for Cancer Therapeutics, where CrossBridge Bio was formed, bringing prior experience from co-founding ReCode Therapeutics.

The company's core business revolves around its proprietary technology platform designed to create dual-payload ADCs. This approach involves attaching two different therapeutic agents to a single antibody, aiming to overcome challenges faced by conventional ADCs such as treatment resistance and side effects. The platform utilizes a unique, highly stable linker technology that ensures the payloads are released specifically within cancer cells, which maximizes therapeutic impact while minimizing harm to healthy tissue. CrossBridge Bio employs microbial transglutaminase (mTG) for precise, site-specific conjugation, allowing for controlled drug-to-antibody ratios and the creation of uniform ADC products.

The business model focuses on advancing a pipeline of ADC programs for treating solid tumors. Its lead candidate, CBB-120, is a TROP-2 dual-payload ADC being developed for solid tumors, including certain types of breast cancer. The company generates capital through financing rounds to fund its research and development. In late 2024, CrossBridge Bio secured $10 million in seed financing from investors including TMC Venture Fund, CE-Ventures, Portal Innovations, and Alexandria Venture Investments. This funding is allocated to advancing CBB-120 into preclinical toxicology studies and further developing the company's linker technology.

Keywords: antibody-drug conjugates, ADC therapeutics, dual-payload ADCs, targeted cancer therapy, oncology, biotechnology, solid tumors, TROP-2, proprietary linker technology, enzymatic conjugation, cancer research, preclinical studies, CBB-120, UTHealth Houston, Texas Medical Center, biopharmaceuticals, drug discovery, molecular medicine, therapeutic index, tumor heterogeneity